新型调理素细胞外CIRP抑制剂MOP3减轻肠道缺血再灌注损伤
本研究探讨新型肽MOP3通过调理细胞外冷诱导RNA结合蛋白(eCIRP)并促进其吞噬清除,能否减轻肠道缺血再灌注(I/R)损伤及继发急性肺损伤。体外实验显示MOP3显著增加肠上皮细胞对FITC标记eCIRP的吞噬(P<0.01)并减少IL-6释放(P<0.001)。成年C57BL/6小鼠经肠系膜上动脉阻断60分钟后再灌注,再灌注时经眶后静脉注射MOP3或溶剂;再灌注后4小时MOP3显著降低血浆IL-1β(P<0.01)、IL-6(P<0.05)和乳酸脱氢酶(P<0.05),降低肠道(P<0.05)与肺(P<0.001)损伤评分及肠道细胞死亡(P<0.05),并逆转肠道ZO-1 mRNA表达下降(P<0.001)。MOP3组36小时死亡率显著降低(P<0.05)。作者认为MOP3有望成为该致命性状况的创新治疗策略。
要点
- 小鼠肠道I/R模型再灌注时经眶后静脉注射MOP3,36小时死亡率较溶剂组显著降低(P<0.05)。
- MOP3显著增加肠上皮细胞对FITC标记eCIRP的吞噬(P<0.01),并减少细胞上清IL-6释放(P<0.001)。
- 再灌注后4小时,MOP3显著降低血浆IL-1β(P<0.01)、IL-6(P<0.05)和乳酸脱氢酶(P<0.05)。
- MOP3显著降低肠道损伤评分(P<0.05)、肺损伤评分(P<0.001)及肠道细胞死亡(P<0.05)。
- MOP3显著逆转肠道I/R后ZO-1 mRNA表达下降(P<0.001),并降低肺趋化因子与MPO水平。
适用人群与场景
- 成年C57BL/6小鼠,经肠系膜上动脉阻断60分钟建立肠道缺血再灌注模型。
处置流程与药物剂量
- 再灌注时经眶后静脉注射MOP3或溶剂;再灌注后4小时采集血、肠、肺组织检测,另设组观察36小时生存。
研究设计与关键结果
- 体外:MOP3显著增加肠上皮细胞对FITC标记eCIRP的吞噬(P<0.01),并显著减少细胞上清IL-6释放(P<0.001)。
- 肠道I/R导致血浆eCIRP水平升高;MOP3显著降低血浆IL-1β(P<0.01)、IL-6(P<0.05)和乳酸脱氢酶(P<0.05)。
- MOP3显著降低肠道损伤评分(P<0.05)、肺损伤评分(P<0.001)及肠道细胞死亡(P<0.05)。
- MOP3降低肠道I/R后肺趋化因子水平和粒细胞活化标志物MPO。
- 肠道I/R后肠道ZO-1表达下降,MOP3显著逆转ZO-1 mRNA表达下降(P<0.001)。
- MOP3组36小时死亡率较溶剂组显著降低(P<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(小鼠肠道I/R模型)与体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为MOP3通过促进eCIRP清除有效减轻肠道I/R所致器官损伤,有望成为该致命性状况的创新治疗策略;当前证据来自小鼠与体外实验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Gut ischemia and reperfusion (I/R) injury promotes the release of damage-associated molecular patterns (DAMPs) such as extracellular cold-inducible RNA-binding protein (eCIRP). Gut I/R often leads to acute lung injury (ALI), a major contributor to mortality. Milk fat globule-epidermal growth factor-factor VIII-derived oligopeptide-3 (MOP3) is a novel peptide that attenuates sepsis by opsonizing eCIRP and facilitating its phagocytic clearance. We hypothesized that MOP3 reduces inflammation, mitigates gut and lung injury, and improves survival in gut I/R injury. Methods: Phagocytosis of FITC-labeled eCIRP by intestinal epithelial cells was determined by confocal microscopy, and the cell supernatant was evaluated for cytokine expression by ELISA. Adult C57BL/6 mice underwent 60 min of gut ischemia via superior mesenteric artery occlusion followed by reperfusion. Mice were treated with MOP3 or vehicle via retro-orbital injection at the time of reperfusion. At 4 h post-I/R, blood, gut, and lungs were harvested for further assay. In additional mice, 36-h survival was assessed. Plasma levels of injury and inflammatory markers were measured with colorimetry and ELISA, respectively. Tissue mRNA expression was measured with qPCR. Myeloperoxidase (MPO), TUNEL, histologic injury, and ZO-1 immunohistochemistry assessments were performed. Results: MOP3 significantly increased eCIRP phagocytosis by intestinal epithelial cells ( P < 0.01) and decreased IL-6 release ( P < 0.001). Gut I/R caused elevated plasma eCIRP levels. MOP3 treatment significantly reduced plasma levels of IL-1β ( P < 0.01), IL-6 ( P < 0.05), and lactate dehydrogenase ( P < 0.05) along with a significant decrease in gut ( P < 0.05) and lung ( P < 0.001) injury scores as well as gut cell death ( P < 0.05). Moreover, MOP3 reduced pulmonary levels of chemokines and the granulocyte activation marker MPO after gut I/R. Mechanistically, ZO-1 expression in the gut was decreased following gut I/R injury, whereas MOP3 significantly reversed the decrease in ZO-1 mRNA expression ( P < 0.001). Finally, mice treated with MOP3 exhibited a significant decrease in mortality ( P < 0.05). Conclusions: Treatment with MOP3 effectively mitigates organ injury induced by gut I/R. This beneficial effect is attributed to the facilitation of eCIRP clearance, directing the potential of MOP3 as an innovative therapeutic approach for this critical and often fatal condition.
参考来源
- Hollis R, Li J, Lee Y, et al. A NOVEL OPSONIC EXTRACELLULAR CIRP INHIBITOR MOP3 ALLEVIATES GUT ISCHEMIA/REPERFUSION INJURY. Shock. 2024. PMID: 39178245. doi:10.1097/SHK.0000000000002467
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。